Jump to main content.


1,3-Butadiene Quickview (CASRN 106-99-0)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for 1,3-Butadiene

File First On-Line: 03/31/1987; Last Significant Revision: 11/05/2002

Category (section)
Status
Last Revised
Oral RfD Assessment No data
Inhalation RfC Assessment On-line 11/05/2002
Carcinogenicity Assessment On-line 11/05/2002
Synonyms
  • 106-99-0
  • Biethylene
  • Bivinyl
  • Butadieen
  • Buta-1,3-dieen
  • Butadien
  • Buta-1,3-dien
  • Butadiene
  • 1,3-Butadiene
  • Butadiene, 1,3-
  • alpha,gamma-Butadiene
  • more...
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Information reviewed but value not estimated. See IRIS Summary.

Top of page


Reference Concentration for Chronic Inhalation Exposure (RfC)

Critical Effect
Point of Departure*
UF RfC
Ovarian atrophy BMCL10 (HEC): 1.98 mg/m3 1000 2x10-3 mg/m3

* The Point of Departure listed serves as a basis from which the Inhalation RfC was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • Carcinogenic to humans
  • Weight-of-Evidence Narrative:
    • Under EPA's 1999 Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), 1,3-butadiene is characterized as carcinogenic to humans by inhalation. This characterization is supported by the total weight of evidence provided by the following: (1) sufficient evidence from epidemiologic studies of the majority of U.S. workers occupationally exposed to 1,3-butadiene, either to the monomer or to the polymer by inhalation, showing increased lymphohematopoietic cancers and a dose-response relationship for leukemias in polymer workers (see Section II.A.2), (2) sufficient evidence in laboratory animal studies showing that 1,3-butadiene causes tumors at multiple sites in mice and rats by inhalation (see Section II.A.3), and (3) numerous studies consistently demonstrating that 1,3-butadiene is metabolized into genotoxic metabolites by experimental animals and humans (see Section II.A.4). The specific mechanisms of 1,3-butadiene-induced carcinogenesis are unknown; however, the scientific evidence strongly suggests that the carcinogenic effects are mediated by genotoxic metabolites of 1,3-butadiene, i.e., the monoepoxide, the diepoxide, and the epoxydiol.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Information reviewed but value not estimated. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

Inhalation Unit Risk(s)
Extrapolation Method
3 x10-5 per µg/m3 Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied.

Inhalation Concentrations at Specified Risk Levels

Risk Level
Concentration
E-4 (1 in 10,000) 3 µg/m3
E-5 (1 in 100,000) 3x10-1 µg/m3
E-6 (1 in 1,000,000) 3x10-2 µg/m3

Top of page


Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research


Local Navigation


Jump to main content.